Polpharma Santo is a leading manufacturer and supplier of affordable and quality medicines in Kazakhstan and Central Asian countries. As a member of the international pharmaceutical Polpharma Group, the company achieves its goal of helping people live healthy lives in a healthy world.

With a portfolio of more than 280 generic drugs in 12 pharmacotherapeutic groups SANTO holds a leading position in the region. In 2025, the company was the first in Central Asia to successfully pass the GMP inspection of the European Union, confirming the compliance of its products with international quality standards.

A key role in the development of the company is played by the Innovation and Quality Centre, which combines a research and development (R&D) centre, a microbiological laboratory and quality control laboratories. The IQC ensures scientific support, technological innovation and consistent product quality at all stages.

Polpharma Santo is implementing the largest investment project in the pharmaceutical industry in the region, aimed at modernizing the production sites and the IQC. The volume of investment exceeds USD 130 million.

The company is represented in Kyrgyzstan and Uzbekistan (under the Polpharma brand) and exports to Russia, Mongolia, Turkmenistan, Tajikistan, Kyrgyzstan and Uzbekistan, while strengthening its position in the domestic market and expanding international co-operation.